Loading
A phase 1/2 trial of Entrectinib in brain and spinal cord tumours, run by Hoffmann-La Roche, active and no longer recruiting.
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options is a phase 1/2 interventional study registered as NCT02650401 by Hoffmann-La Roche, with 69 participants enrolled, started 2016-05-03 and due to reach its primary completion in 2026-06-30. Interventions recorded: Entrectinib.
Shares Flatiron Health (Roche), Brain and spinal cord tumours (all types), Small-molecule kinase inhibitors and the tag pipeline.
Shares Entrectinib, Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche) and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Brain and spinal cord tumours (all types), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Small-molecule kinase inhibitors and the tag pipeline.
Shares Flatiron Health (Roche) and the tag pipeline.